文献速递类风湿关节炎

疾病病程与既往DMARD使用对类风湿关节炎治疗结局的影响

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2019-08-21

基于两项随机对照试验数据,评估已确诊类风湿关节炎(平均病程11年)患者中,病程长短和既往改善病情抗风湿药(DMARD)数量对阿达木单抗联合甲氨蝶呤治疗反应的影响。结果显示,既往DMARD数量较多和病程较长与第24周疗效改善幅度较小及ACR应答率较低相关,且既往DMARD数量对治疗反应的限制作用独立于病程。

要点

  • 既往DMARD数量>2种较0-1种与第24周DAS28(CRP)、SDAI和HAQ-DI改善幅度更小相关。
  • RA病程>10年较<1年与第24周HAQ-DI评分更高相关,但DAS28(CRP)和SDAI结果不一。
  • 既往DMARD数量较多和病程较长均与第24周ACR应答率较低相关。

核心结论

  • 既往DMARD数量和疾病病程影响已确诊RA患者对阿达木单抗联合甲氨蝶呤的治疗反应。
  • 既往DMARD数量无论病程长短,均对阿达木单抗治疗的潜在反应具有限制作用。

研究设计与样本

  • 基于两项随机对照试验数据,纳入已确诊RA患者(平均病程11年),均接受阿达木单抗+甲氨蝶呤治疗。
  • 较大规模研究N=207,第二项试验N=67。

主要发现

  • 较大规模研究中,既往DMARD>2种 vs 0-1种:DAS28(CRP)改善-1.8 vs -2.2,SDAI改善-22.1 vs -26.9,HAQ-DI改善-0.43 vs -0.64(基线至第24周)。
  • RA病程>10年 vs <1年:第24周HAQ-DI评分1.1 vs 0.7,但DAS28(CRP)和SDAI结果不一。
  • 既往DMARD数量较多和RA病程较长与第24周ACR应答率较低相关,第二项试验(N=67)数据总体证实这些发现。

关键数值与推荐

  • 疗效评估指标包括DAS28(CRP)、SDAI、HAQ-DI及ACR 20%/50%/70%应答率,评估时间为第24周。

临床怎么用

  • 对已确诊RA患者,既往DMARD数量较多或病程较长时,应预期对阿达木单抗联合甲氨蝶呤的疗效可能受限。
  • 既往DMARD数量对治疗反应的限制作用独立于病程,临床决策时需综合考虑这两方面因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA). METHODS: Associations between disease duration or number of prior DMARDs and response to therapy were assessed using data from two randomised controlled trials in patients with established RA (mean duration, 11 years) receiving adalimumab+methotrexate. Response to therapy was assessed at week 24 using disease activity outcomes, including 28-joint Disease Activity Score based on C-reactive protein (DAS28(CRP)), Simplified Disease Activity Index (SDAI) and Health Assessment Questionnaire Disability Index (HAQ-DI), and proportions of patients with 20%/50%/70% improvement in American College of Rheumatology (ACR) responses. RESULTS: In the larger study (N=207), a greater number of prior DMARDs (>2 vs 0-1) was associated with smaller improvements in DAS28(CRP) (-1.8 vs -2.2), SDAI (-22.1 vs -26.9) and HAQ-DI (-0.43 vs -0.64) from baseline to week 24. RA duration of >10 years versus <1 year was associated with higher HAQ-DI scores (1.1 vs 0.7) at week 24, but results on DAS28(CRP) and SDAI were mixed. A greater number of prior DMARDs and longer RA duration were associated with lower ACR response rates at week 24. Data from the second trial (N=67) generally confirmed these findings. CONCLUSIONS: Number of prior DMARDs and disease duration affect responses to therapy in patients with established RA. Furthermore, number of prior DMARDs, regardless of disease duration, has a limiting effect on the potential response to adalimumab therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Aletaha D, Maa JF, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019. PMID: 31434637. doi:10.1136/annrheumdis-2018-214918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。